Hematopoietic stem cells: Ex-vivo expansion and therapeutic potential for myocardial ischemia

Jingwei Lu, Vincent J. Pompili, Hiranmoy Das

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Despite recent advances in cardiovascular medicine, ischemic heart disease remains the major cause of death in the United States and abroad. Cell-based therapy for degenerative diseases like myocardial ischemia using stem cells is currently under serious investigation. Various types of stem cells are being considered to be candidates for cell transplantation in cell-based therapy. Hematopoietic stem cells are one of the most promising cell types as several studies demonstrated their ability to improve ischemic cardiac functions by enhancing neovascularization and by reducing the total size of scar tissue. However, in order to procure sufficient numbers of functional stem cells, ex-vivo expansion technology became critically important. In this review, we focus on the state-of-the-art ex-vivo technology for the expansion of hematopoietic stem cells, and the underlying mechanisms regulating stem cell self-renewal as well as differentiation.

Original languageEnglish (US)
Pages (from-to)57-68
Number of pages12
JournalStem Cells and Cloning: Advances and Applications
Volume3
Issue number1
StatePublished - Nov 1 2010

Fingerprint

Hematopoietic Stem Cells
Myocardial Ischemia
Stem Cells
Cell- and Tissue-Based Therapy
Technology
Cell Transplantation
Cicatrix
Cause of Death
Therapeutics
Medicine

Keywords

  • Cytokines
  • Ex-vivo expansion
  • Hematopoietic stem cells
  • Ischemic heart disease
  • Nanofibers

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Cell Biology

Cite this

Hematopoietic stem cells : Ex-vivo expansion and therapeutic potential for myocardial ischemia. / Lu, Jingwei; Pompili, Vincent J.; Das, Hiranmoy.

In: Stem Cells and Cloning: Advances and Applications, Vol. 3, No. 1, 01.11.2010, p. 57-68.

Research output: Contribution to journalReview article

@article{894b12a2be7e465988020f7bbbd5ece9,
title = "Hematopoietic stem cells: Ex-vivo expansion and therapeutic potential for myocardial ischemia",
abstract = "Despite recent advances in cardiovascular medicine, ischemic heart disease remains the major cause of death in the United States and abroad. Cell-based therapy for degenerative diseases like myocardial ischemia using stem cells is currently under serious investigation. Various types of stem cells are being considered to be candidates for cell transplantation in cell-based therapy. Hematopoietic stem cells are one of the most promising cell types as several studies demonstrated their ability to improve ischemic cardiac functions by enhancing neovascularization and by reducing the total size of scar tissue. However, in order to procure sufficient numbers of functional stem cells, ex-vivo expansion technology became critically important. In this review, we focus on the state-of-the-art ex-vivo technology for the expansion of hematopoietic stem cells, and the underlying mechanisms regulating stem cell self-renewal as well as differentiation.",
keywords = "Cytokines, Ex-vivo expansion, Hematopoietic stem cells, Ischemic heart disease, Nanofibers",
author = "Jingwei Lu and Pompili, {Vincent J.} and Hiranmoy Das",
year = "2010",
month = "11",
day = "1",
language = "English (US)",
volume = "3",
pages = "57--68",
journal = "Stem Cells and Cloning: Advances and Applications",
issn = "1178-6957",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Hematopoietic stem cells

T2 - Ex-vivo expansion and therapeutic potential for myocardial ischemia

AU - Lu, Jingwei

AU - Pompili, Vincent J.

AU - Das, Hiranmoy

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Despite recent advances in cardiovascular medicine, ischemic heart disease remains the major cause of death in the United States and abroad. Cell-based therapy for degenerative diseases like myocardial ischemia using stem cells is currently under serious investigation. Various types of stem cells are being considered to be candidates for cell transplantation in cell-based therapy. Hematopoietic stem cells are one of the most promising cell types as several studies demonstrated their ability to improve ischemic cardiac functions by enhancing neovascularization and by reducing the total size of scar tissue. However, in order to procure sufficient numbers of functional stem cells, ex-vivo expansion technology became critically important. In this review, we focus on the state-of-the-art ex-vivo technology for the expansion of hematopoietic stem cells, and the underlying mechanisms regulating stem cell self-renewal as well as differentiation.

AB - Despite recent advances in cardiovascular medicine, ischemic heart disease remains the major cause of death in the United States and abroad. Cell-based therapy for degenerative diseases like myocardial ischemia using stem cells is currently under serious investigation. Various types of stem cells are being considered to be candidates for cell transplantation in cell-based therapy. Hematopoietic stem cells are one of the most promising cell types as several studies demonstrated their ability to improve ischemic cardiac functions by enhancing neovascularization and by reducing the total size of scar tissue. However, in order to procure sufficient numbers of functional stem cells, ex-vivo expansion technology became critically important. In this review, we focus on the state-of-the-art ex-vivo technology for the expansion of hematopoietic stem cells, and the underlying mechanisms regulating stem cell self-renewal as well as differentiation.

KW - Cytokines

KW - Ex-vivo expansion

KW - Hematopoietic stem cells

KW - Ischemic heart disease

KW - Nanofibers

UR - http://www.scopus.com/inward/record.url?scp=77953761052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953761052&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77953761052

VL - 3

SP - 57

EP - 68

JO - Stem Cells and Cloning: Advances and Applications

JF - Stem Cells and Cloning: Advances and Applications

SN - 1178-6957

IS - 1

ER -